Karthikeyan Murugesan

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

Mark Yarchoan, Lee A. Albacker, Alexander C. Hopkins et al. · JCI Insight · 2019 · 526 citations · Full text

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Marcelo V. Negrão, Ferdinandos Skoulidis, Meagan Montesion et al. · Journal for ImmunoTherapy of Cancer · 2021 · 269 citations · Full text

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response

Meagan Montesion, Karthikeyan Murugesan, Dexter X. Jin et al. · Cancer Discovery · 2020 · 231 citations · Full text

Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma

Gajanan Kendre, Karthikeyan Murugesan, Tilman Brummer et al. · Journal of Hepatology · 2022 · 142 citations · Full text

Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).

Milind Javle, Karthikeyan Murugesan, Rachna T. Shroff et al. · Journal of Clinical Oncology · 2019 · 61 citations

Cancer Pathology, Genetics, Immunology +22